Market Overview

UPDATE: Citigroup Downgrades Edwards Lifesciences Corp. to Neutral, Lowers PT

Share:
Related EW
BMO On Abbott Labs: 'It's Likely Time For The Stock To Take A Pause'
Watch These 8 Huge Call Purchases In Tuesday Trade

In a report published Friday, Citigroup downgraded its rating on Edwards Lifesciences Corp. (NYSE: EW) from Buy to Neutral, and lowered its price target from $101.00 to $95.00.

Citigroup noted, “We rate Edwards Lifesciences (EW) Neutral. The near term ramp in US TAVI will likely take longer to materialize than originally expected despite recent approval of Cohort A, and combined with the macro issues in Europe that continue to add uncertainty to the global TAVI market, we believe visibility on the near-term market opportunity is limited despite believing that the longer-term opportunity remains intact.”

Edwards Lifesciences Corp. closed on Thursday at $86.14.

Latest Ratings for EW

DateFirmActionFromTo
Feb 2017BTIG ResearchDowngradesBuyNeutral
Jan 2017GuggenheimUpgradesNeutralBuy
Dec 2016Cowen & Co.MaintainsOutperformOutperform

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Downgrades Analyst Ratings

 

Related Articles (EW)

View Comments and Join the Discussion!